Unable to display view head.php file not found.
The second long-term study with dabigatran is RE-SONATE. In this trial, patients who had completed 6 or 18 months of anticoagulant therapy were randomized to dabigatran etexilate at a dose of 150 mg twice daily or placebo. This means that RE-SONATE differed from the RE-MEDY trial because the comparator was warfarin whereas in RE-SONATE the comparator was placebo.[9] Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.
[9] Schulman S, Kearon C, Kakkar AK, et al; for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-718.